Description
Created On: 2020-07-15
Record Count: 5
Primary Industries
- Drugs
- Delivery
- Pain
- Cancer
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 289191
under the Licensed Technology to market, advertise, promote, distribute for commercial sale, offer
for sale, sell, and import for commercial sale the Licensed Product in the Territory and Licensor
hereby grants a non-exclusive license, without rights of sublicense, under the Licensed Technology to develop in the Territory the Licensed Product for additional human therapeutic indications following Governmental Approval of such Licensed Product in the Territory for the Initial Indication.
Product means the Licensed Product, Placebos, and Demonstration Samples.
The Drug Product is BEMA rM Fentanyl, Bucco/ Soluble Film
BEMA means the proprietary bioerodible, mucoadhesive multi-layer polymer film technology Controlled by Licensor.
The Field means the treatment of breakthrough cancer pain in patients tolerant to opioids, the Initial Indication, and, following Governmental Approval in the Territory of the Licensed Product for the Initial Indication, any additional human therapeutic indications for which Governmental Approval is obtained.
IPSCIO Record ID: 256300
The Parties wish to cooperate in the exclusive manufacturing of the Products and Placebos in the Territory.
The Active Principle shall mean Fentanyl.
The Product shall mean Licensees transmucosal oral system containing Active Principle based on the Design of Licensee Technology.
Licensee has bioerodable mucoadhesive transmucosal technology.
Licensor has technology and process for oral film form products and/or pharmaceutical preparations in general, their use, process development, including without limitation the mass preparation, coating, drying and compiling thereof, and, manufacturing, packaging, and labeling.
U.S. Patents Nos. 5,948,430, 6,177,096 and 6,284,264
The Licensee lead BEMAâ„¢ product under development is BEMAâ„¢ Fentanyl, a treatment for breakthrough cancer pain.
IPSCIO Record ID: 212269
Licensee will be responsible for the manufacturing, distribution, marketing and sales of ONSOLIS in the U.S.
IPSCIO Record ID: 4069
The BEMA® drug delivery technology is a buccal soluble film consisting of a small, BioErodible polymer film for application to the mucosal membranes (inner lining of cheek). BEMA® films were designed to rapidly deliver a dose of drug across the mucous membranes for time sensitive conditions.
IPSCIO Record ID: 282856
Licensor hereby grants to Licensee a sole and exclusive, royalty-free license to use the Marks solely in connection with the use, promotion, marketing, distribution, offer for sale, and sale of the Products, on a Product-by-Product basis, in the Territory during the Royalty Term. Licensee may grant a sublicense to the Marks in accordance with this agreement.
Marks means “BEMA†or any additional trademarks owned by Licensor with respect to the BEMA Technology, alone or accompanied by any logo or design and any non-English language equivalents in figure, sound or meaning, whether registered or not.
Product means individually and collectively any product which, but for the licenses granted under this Agreement, would infringe one or more valid claims of the BEMA Patent Rights.
Fentanyl Product means the first Product containing Fentanyl, used for the treatment of pain and sold in a Commercial Sale.
BEMA Patent Rights means all Patent Rights in the Territory related to the patents and patent applications listed, claiming BEMA or any Improvement, or which are necessary or appropriate to develop, manufacture and commercialize Products in the Territory, and that are under the Control of Licensor as of the Effective Date or that come under Licensors Control during the Term.
5,800,832 – Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
6,159,498 – Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces
BEMA Technology means the BEMA Patent Rights and the BEMA Know How.
Patent Rights means all rights under patents and patent applications, and any and all patents issuing therefrom (including utility, model and design patents and certificates of invention), together with any and all substitutions, extensions (including supplemental protection certificates), registrations, confirmations, reissues, divisionals, continuations, continuations-in-part, re-examinations, renewals and foreign counterparts of the foregoing, and all improvements, supplements, modifications or additions.
The BEMA(TM) technology allows for the delivery of drugs across the buccal (i.e., mouth) mucosa that provides a rapid onset of therapeutic effect and a competitive advantage in such areas as pain relief and sedation.